Ventyx Biosciences Inc

Ventyx Biosciences — Investor Presentation (November 2021)

33 slides from Ventyx Biosciences's investor presentation, Nov 30, 2021

  1. Slide 1: Corporate Presentation Fourth Quarter 2021

    Exhibit 99.1 Corporate Presentation Fourth Quarter 2021 PAGE 1

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements Ventyx cautions you that statements contained in this presentation regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. Such forward-looking statements include, but are

  3. Slide 3: Summary Milestones & Highlights

    COMPANY VTX958 PHASE 1 VTX002 PHASE 2 READY VTX2735 PHASE 1 CNS NLRP3 PRECLINICAL SUMMARY MILESTONES & HIGHLIGHTS PAGE 3

  4. Slide 4: Our Leadership Team

    Our Leadership Team Raju Mohan, PhD CHIEF EXECUTIVE OFFICER, FOUNDER Sheila Gujrathi, MD Aaron Royston, MD EXECUTIVE CHAIR, VENTYX MANAGING PARTNER, VENBIO Jigar Choksey Martin Auster, MD Chris Krueger, JD Somu Subramaniam PRINCIPAL, THIRD POINT CHIEF FINANCIAL OFFICER CHIEF BUSINESS OFFICER MANAGIN

  5. Slide 5: Our Mission: To become a Leading Immunology Company

    Our Mission: To become a Leading Immunology Company continue to generate candidates allow us to own 100% and a deep pipeline of preclinical with potential to address commercial rights to our entire programs that target immune- diseases with high unmet need portfolio with long patent lives for mediat

  6. Slide 6: Broad Pipeline of Candidates With Multiple Near-Term Catalysts

    Broad Pipeline of Candidates With Multiple Near-Term Catalysts TARGET PROGRAM PRECLINICAL PHASE 1 PHASE 2 PHASE 3 NEXT ANTICIPATED MILESTONES Complete Phase 1 MAD H1 2022 TYK2 VTX958 Initiate Phase 2 POC trial(s) H2 2022 Potential indications include psoriasis, psoriatic arthritis, Crohn’s disease a

  7. Slide 7: VTX958 Orally Bioavailable, Selective Allosteric Inhibitor of TYK2

    COMPANY TEAM, INVESTORS, & PIPELINE VTX958 VTX002 PHASE 2 READY VTX2735 PHASE 1 Orally Bioavailable, CNS NLRP3 Selective Allosteric PRECLINICAL Inhibitor of TYK2 SUMMARY MILESTONES & HIGHLIGHTS PAGE 7

  8. Slide 8: VTX958 Program Summary

    VTX958 Program Summary • Multiple autoimmune disorders • Selective, allosteric TYK2 inhibitor • Well established clinical efficacy in dermatology, IBD, renal and in psoriasis, IBD and psoriatic • TYK2 functional selectivity can rheumatology total $45B WW arthritis with biologics targeting potentiall

  9. Slide 9: Allosteric Inhibitor VTX958 Binds Selectively to the TYK2 JH2 Domain

    Allosteric Inhibitor VTX958 Binds Selectively to the TYK2 JH2 Domain IL-12, Inhibited Active Inactive IL-23, IFNa Selectivity for TYK2 JH2 vs. JAK1 JH2 FERM/SH2 Receptor interaction domain (>4,000 X) JH2 Allosteric Domain Much less conserved amongst the No binding to JAK2/3 JAK family with structura

  10. Slide 10: VTX958 More Selective than Deucravacitinib for TYK2 JH2 Domain

    VTX958 More Selective than Deucravacitinib for TYK2 JH2 Domain IL-2, IL-4 IL-10,IL-22 IFNα/β IL-12/23 IFNγ IL-13, IL-15 IL-6 DEUCRAVACITINIB TYK2-JH2 Binding K 0.009 nM 0.058 nM d JAK1 TYK2 JAK1 TYK2 JAK1 JAK1 JAK1-JH2 Binding K 0.43 nM 240 nM d other JAK JAK2 JAK3 JAK2 Selectivity (fold) 48 >4,000

  11. Slide 11: VTX958 Selectively Targets IL-12, IL-23 and IFNa

    VTX958 Selectively Targets IL-12, IL-23 and IFNa Proinflammatory Innate & Th1/Th17 Cytokines Psoriasis Patient PBMC Selective and potent IL-23 IFNα IL-12 Drug Potent activity IC (nM) IC (nM) 50 IC (nM) 50 50 inhibition of IL-12/23 and against IL-23, a Type I interferon axis VTX958 35 5 12 key cytoki

  12. Slide 12: VTX958 Phase 1 SAD Results Support Clinical Advancement

    VTX958 Phase 1 SAD Results Support Clinical Advancement Well-tolerated across all No dose-saturation observed; PK Dose-dependent VTX958-mediated effect on cohorts; all AEs observed and absorption profiles suggest continued TYK2 signaling observed in both in vivo were mild and not dose- or absorption

  13. Slide 13: VTX958 Clinical Development Plan

    VTX958 Clinical Development Plan Phase 1 MAD Phase 2 PoC • All 7 cohorts • Explore safety and completed exposure data on Phase 2 PoC Phase 2 trials planned in repeat dosing • Safety and additional indications Initial Phase 2 trial in exposure data allow (psoriatic arthritis, Crohn’s • Elucidate PD p

  14. Slide 14: Commercial Potential in Large Well-Established Markets

    Commercial Potential in Large Well-Established Markets INDICATION* PATIENTS IN THE U.S. GLOBAL DRUG REVENUE* (2020) TARGET POPULATION Psoriasis 25-30% ~8M ~$20B Dermatology MODERATE-TO-SEVERE Crohn’s disease 30-40% ~700K ~$13B IBD MODERATE-TO-SEVERE Ulcerative colitis 30-40% ~1M ~$7B IBD MODERATE-TO

  15. Slide 15: Psoriasis and Psoriatic Arthritis

    Psoriasis and Psoriatic Arthritis • ~1M patients in U.S. • ~8M patients in U.S. • Significant share shift in recent years • Up to ~40-60% are moderate-to-severe • 25-30% are moderate-to-severe from anti-TNF agents to newer • Total treated U.S. moderate-severe • U.S. biologic penetration ~15-20% biol

  16. Slide 16: Crohn's Disease

    Crohn’s Disease • ~700k+ Crohn’s disease patients in U.S. • ~$13B market dominated by • 30-40+% are moderate-to-severe • U.S. biologic penetration ~35-40% parenteral biologic therapies • Global revenue of Crohn’s disease drugs ~$13B in 2020 • Share trends have favored Stelara (anti-IL-12/23) with mo

  17. Slide 17: VTX002 Peripherally Restricted S1P1R Modulator for Ulcerative Colitis

    COMPANY TEAM, INVESTORS, & PIPELINE VTX958 PHASE 1 VTX002 VTX2735 PHASE 1 Peripherally Restricted S1P1R CNS NLRP3 Modulator with Potential for Treatment PRECLINICAL of Ulcerative Colitis SUMMARY MILESTONES & HIGHLIGHTS PAGE 17

  18. Slide 18: VTX002 Program Summary

    VTX002 Program Summary • Selective S1P1R modulator • S1P1R modulators approved for • Ulcerative colitis is lead MS and UC with clinical trials indication totaling up to $7B in • Differentiated on key parameters ongoing in other indications worldwide revenue • Demonstrated pharmacodynamic • BMS’ ozan

  19. Slide 19: VTX002 Differentiates on Multiple Key Parameters vs. Competitors

    VTX002 Differentiates on Multiple Key Parameters vs. Competitors No CYP inhibition; no food effect; favorable No SAEs, elevated LFTs, abnormal profile for patients with co-morbidities Sustained lymphocyte reduction up to 65% PFTs or macular edema across multiple doses in MAD trial Very low CNS penet

  20. Slide 20: Phase 1 MAD Results: Dose-Dependent Exposure and Lymphocyte Reduction

    Phase 1 MAD Results: Dose-Dependent Exposure and Lymphocyte Reduction 0 -20 -40 -60 ****p< 0.0001 **** **** **** **** **** **** **** **** -80 Placebo 2 mg 10 mg 20 mg 35 mg 45 mg • T of ~20 hours 1/2 • Demonstrated consistent, sustained reduction of lymphocytes up to 65% across multiple dose groups

  21. Slide 21: Phase 2 Trial in Moderate-to-Severe Ulcerative Colitis Patients

    Phase 2 Trial in Moderate-to-Severe Ulcerative Colitis Patients N=180; 1:1:1 Powered for primary endpoint of clinical 13-Week Induction Treatment 39-Week, Open-Label Extension Treatment (7-day titration + 12 weeks placebo/target dose) 7-day titration + 38 weeks 60 mg dose remission 39 weeks Yes VTX0

  22. Slide 22: Underpenetrated Market for Biologic Refractory Patients

    Underpenetrated Market for Biologic Refractory Patients • Existing agents leave room for new treatments ~1M UC PATIENTS • Novel oral agents may expand penetrance of treated moderate-to- 300K+ severe UC population MODERATE-TO-SEVERE UC PATIENTS beyond current ~25- 30% ~100K • S1P well positioned to B

  23. Slide 23: VTX2735 and CNS NLRP3 Inhibitors

    COMPANY TEAM, INVESTORS, & PIPELINE VTX958 PHASE 1 VTX002 PHASE 2 READY VTX2735 CNS NLRP3 Selective NLRP3 Inflammasome Inhibitors for Systemic and CNS Indications SUMMARY MILESTONES & HIGHLIGHTS PAGE 23

  24. Slide 24: Rationale for Targeting the NLRP3 Inflammasome

    Rationale for Targeting the NLRP3 Inflammasome • The NLRP3 inflammasome can • Gain-of-function mutations in the become overactive in the presence of NLRP3 gene, associated with • IL-1β signaling, downstream of persistent tissue damage or crystal certain severe orphan inflammatory inflammasome activa

  25. Slide 25: NLRP3 Inhibitor Program Summary

    NLRP3 Inhibitor Program Summary • Selective NLRP3 inhibitor • Currently in late-stage lead optimization • Well tolerated in GLP safety and tox assessment • Selective compounds generated with high CNS bioavailability • Phase 1 dosing initiated in Q4 2021 • Novel and proprietary lead series • High ora

  26. Slide 26: VTX2735 is a Selective & Orally Bioavailable NLRP3 Inhibitor

    VTX2735 is a Selective & Orally Bioavailable NLRP3 Inhibitor IV Clearance: 1.6 mL/min/kg; Oral Bioavailability: 80% IL-1ß VTX2735 IC (nM) 50 human 2 On monocytes Target human 48 whole blood AIM2 >10000 Off NLRC4 >10000 Target NF-kb >10000 • Well-tolerated preclinically in IND-enabling GLP studies •

  27. Slide 27: VTX2735 Has Broad Activity Against Multiple NLRP3 Mutations

    VTX2735 Has Broad Activity Against Multiple NLRP3 Mutations An ultra-orphan auto- inflammatory disease caused by various mutations in NLRP3 and characterized by 75% MOST inappropriate release of IL-1β of all CAPS patients SEVERE and symptoms of recurrent In North America systemic inflammation FCAS1

  28. Slide 28: NLRP3 Program Clinical Development Plan

    NLRP3 Program Clinical Development Plan Initiate Phase 2 Indication to be disclosed Healthy volunteers COMPLETE September 2021 Q4 Q4 2 20 02 21 1 2022 PERIPHERALLY-RESTRICTED Select Lead Candidate Potential indications include Parkinson’s, Alzheimer’s, etc. Q4 2021 PAGE 28

  29. Slide 29: Our Comprehensive NLRP3 Portfolio Targets a Broad Range of Major Inflammatory Diseases

    Our Comprehensive NLRP3 Portfolio Targets a Broad Range of Major Inflammatory Diseases CNS-directed NLRP3 inhibitors are Peripheral NLRP3 inhibitors are Alzheimers’ Disease Cardiovascular designed to treat a range of neuro- designed to treat cardiovascular, degenerative disorders, such as rheumatic,

  30. Slide 30: Summary

    COMPANY TEAM, INVESTORS, & PIPELINE VTX958 PHASE 1 VTX002 PHASE 2 READY VTX2735 PHASE 1 CNS NLRP3 PRECLINICAL SUMMARY PAGE 30

  31. Slide 31: Projected Catalysts Over Next Months

    Projected Catalysts Over Next 24 Months PROGRAMS H1’2021 H2’2021 H1’2022 H2’2022 2023 Phase 1 MAD Phase 2 in Multiple Indications* Phase 1 SAD Allosteric TYK2 inhibitor addressing a broad range of autoimmune disorders VTX002 Phase 2 Ulcerative Colitis 13-Week Induction Selective S1P1R modulator targ

  32. Slide 32: Investment Highlights

    Investment Highlights Over $339 million raised from Multiple selective, oral, dedicated biotech small molecule product Our portfolio can address I&I Internal R&D engine investors candidate portfolio: markets, such as psoriasis, designed to generate Cash balance of IBD, and other indications candidat

  33. Slide 33: Contact us for additional information

    Contact us for additional information: [email protected] Ventyx Biosciences, Inc. 662 Encinitas Boulevard, Suite 250 Encinitas, CA 92024 PAGE 33

Ventyx Biosciences — Investor Presentation (November 2021) on 6ix